The darlings of the weight loss and diabetes spaces, GLP-1 receptor agonists have shown promise against Alzheimer’s in recent studies—with Phase III results expected next year from Novo Nordisk.
In this edition of Newsmaker, FOX 10's John Hook first talks with Dr. Swathi Varanasi-Diaz about the impact of weight loss ...
Despite this escalating demand for popular GLP-1 drugs, the prices for some of these products are actually dropping. Dr.
Propensity-score matched analysis showed that VTE rates at 1 year were 20% lower for patients starting on a GLP-1 drug rather ...
As demand for obesity drugs like Wegovy, Zepbound, Mounjaro and Ozempic, outpaces supply, online scams are rising, according ...
An innovative combination of readily available natural products has shaped up to be an alternative to drugs like Ozempic to ...
So much of the joy of Christmas is eating and drinking with wild abandon and dealing with the consequences for your waistline ...
Last week, the Biden administration passed a rule allowing for the government healthcare programs Medicare and Medicaid ...
A new crop of evidence — both anecdotal and research based — is pointing to these drugs as a potential option for people ...
As Ozempic keeps flying off the shelves, more and more people are taking the drug into their own hands by "microdosing" it.
Novo Nordisk is a bargain stock with tremendous growth potential. Vertex Pharmaceuticals has seven clear paths to growth ...